• Automated Point Of Care
    DR Screening

    The number of people with vision loss from diabetic retinopathy has grown significantly over the years creating a growing need for expanding DR screening. EyeArt provides fully automated DR screening, including imaging, grading for DR in accordance with internationally recognized standards, and reporting in a single office visit. EyeArt™ is approved by EU as a Class IIa medical device for sales in Europe.

    Read more
    slide
  • Retinopathy Monitoring
    using Image-based
    Biomarkers

    EyeMark consists of a set of tools for automated computation of biomarkers for diabetic retinopathy (DR) using retinal fundus images. Specifically, it computates microaneurysm (MA) appearance and disappearance rates (jointly known as turnover rates) for use as a biomarker in monitoring progression of DR. The availability of a reliable image-based biomarker is expected to have high positive influence on various aspects of DR care, including screening, monitoring progression, drug discovery and clinical research..

    Read more


    slide
  • DR Screening Using Cellphone-based Cameras

    An end-to-end point-of-care diabetic retinopathy diagnostic device comprising an Ocular CellScope, a cellphone-based retinal imaging camera and an image analysis software enabling fully-automated screening for DR.

    Read more


    slide
  • Automated AMD Screening

    Age-related macular degeneration (AMD) is the single largest cause for legal blindness among senior Americans. Without a straightforward, reliable way to screen for these vulnerable patients, early detection and treatment remains a problem. EyeSeeAMD™ performs a robust, automated screening test for AMD that can be performed by a primary health care provider or an optometrist, who can then refer the patient to an eye specialist, if required.

    Read more


    slide
  • icon

    EyeArt™

  • icon

    EyeMark™

  • icon

    EyeApp™

  • icon

    EyeSeeAMD™

Fully automate your DR screening with EyeArt™

Imaging, grading for diabetic retinopathy, and reporting in a single office visit.